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Bacterial vaginosis (BV), a condition aﬀecting millions of women each year, is primarily caused by the gram-variable organism
Gardnerellavaginalis.AnumberoforganismsassociatedwithBVcaseshavebeenreportedtodevelopmultidrugresistance,leading
to the need for alternative therapies. Previously, we reported the antimicrobial peptide subtilosin has proven antimicrobial activity
against G. vaginalis, but not against the tested healthy vaginal microbiota of lactobacilli. After conducting tissue sensitivity assays
usinganectocervicaltissuemodel,wedeterminedthathumancellsremainedviableafterprolongedexposurestopartially-puriﬁed
subtilosin,indicatingthecompoundissafeforhumanuse.Subtilosinwasshowntoeliminatethemotilityandforwardprogression
of human spermatozoa in a dose-dependent manner, and can therefore be considered a general spermicidal agent. These results
suggest subtilosin would be a valuable component in topical personal care products aimed at contraception and BV prophylaxis
and treatment.
Copyright © 2008 Katia E. Sutyak et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Subtilosin is a ribosomally-synthesized cyclopeptide pro-
duced by Bacillus subtilis ATCC 6633 and a recently iden-
tiﬁed natural isolate of Bacillus amyloliquefaciens [1, 2].
This protein has a unique structure among bacteriocins
[3], and possesses antimicrobial activity against a variety
of pathogenic organisms, including Gardnerella vaginalis,
Listeria monocytogenes,a n dStreptococcus agalactiae (Group
B Streptococcus)[ 2]. The ability to inhibit the growth of
G. vaginalis is of particular importance as it is one of
the primary causative agents for bacterial vaginosis (BV),
a common condition found in up to 30% of women in
North America [4]. BV is characterized by the replacement
of normal vaginal lactobacilli with anaerobic bacteria (e.g.,
Prevotella, Bacteroides,a n dMobiluncus) and mycoplasmas,
as well as a several log increase in overall bacterial growth
[5–7]. BV is asymptomatic in approximately one half of all
cases, but is associated with a wide variety of symptoms and
problems ranging from complications with pregnancies (i.e.,
preterm births, low fetal birth weight) to the development
of pelvic inﬂammatory disorder [7–11]. Recent studies have
estimatedthatnearlyoneinthreewomenintheUnitedStates
(29.2%) suﬀer from BV, with varying prevalence according
to ethnicity and education levels [4]. One of the most
troubling aspects of BV infection is the association with an
increasedriskofseveralsexuallytransmitteddiseases(STDs),
includingchlamydia,herpes,gonorrhea,trichomoniasis,and
HIV/AIDS [12–16]. The treatments recommended by the
Centers for Disease Control (CDC) are clindamycin and
metronidazole administered either orally or intravaginally
[17].Followingtheseguidelinessuccessfullytreats60%ofBV
cases, but 20% of these cases return with highly developed
antibiotic resistances [18–20]. In such cases, it would be
extremely desirable to have an alternative form of treatment
that could fully eradicate the infection.2 Infectious Diseases in Obstetrics and Gynecology
Bacteriocins are typically divided into two major, yet
diverse, classes: class I, or lantibiotics, contain unusual
amino acids and are subject to extensive posttranslational
modiﬁcations; and class II, the heat stable nonlantibiotics
[21]. Subtilosin has a unique posttranslational structure
that is unmatched among bacteriocins, which has led to
speculation that it may belong in a distinct and separate
class [2, 3]. Bacteriocins have been widely considered for use
in medicinal and pharmaceutical applications, particularly
for their bactericidal activity against multidrug resistant
organisms [22]. They are especially appealing alternatives
since their cost of production is so comparatively low
to conventional pharmaceutical treatments. For example,
commercial grade nisin costs approximately $100/lb through
chemical distributors. Much attention has recently been
focused on the spermicidal activity of bacteriocins due to
their targeted antibacterial activity and lack of eﬀect on
human tissues. Nisin A, a well-studied class I bacteriocin
produced by Lactococcus lactis subsp. lactis [23], has human
spermicidal activity [24, 25], and subtilosin has spermicidal
activity against boar, bovine, horse, and rat spermatozoa
[26]. The results of these previous studies suggest that
subtilosin may also have spermicidal activity against human
spermatozoa, prompting our investigation.
Since subtilosin has proven antimicrobial activity against
the pathogen largely responsible for BV, its toxicity to
human tissues was assayed to determine its potential as
a safe alternative remedy. For the human in vitro study,
the EpiVaginal ectocervical tissue model (MatTek Corpora-
tion, Ashland, Mass, USA) was employed to examine the
relationship between prolonged exposure to subtilosin and
cell viability. Spermicidal evaluations were conducted to
investigate the ability of the peptide to restrict or eliminate
sperm mobility, leading to its classiﬁcation as a spermicidal
agent.
2. MATERIALS AND METHODS
2.1. Productionofsubtilosin
Subtilosin was prepared as previously described [2]. To
prepare a cell-free supernatant (CFS), cells were removed
by centrifugation (Hermle Z400K; LabNet, Woodbridge, NJ,
USA) for 25 minutes at 4500g and 4◦C. The supernatant
was ﬁlter sterilized using 0.45μm ﬁlters (Fisher, Pittsburgh,
Pa, USA). The protein of interest was precipitated from the
supernatant by adding 30% ammonium sulfate (w/v) while
stirring overnight at 4◦C and was resuspended in 20mL of
double distilled H2O. The column chromatography method
described by Sutyak et al. [2] was used to purify subtilosin
from the CFS, producing a near-pure isolate in the 90%
methanol eluate. The antimicrobial activity of all samples
was conﬁrmed by the well-diﬀusion assay according to the
protocol of Cintas et al. [27] with additional modiﬁcations
[2]. The active fraction was concentrated to dryness using
a Savant SC110 Speed Vac and UVS400 Universal Vacuum
System (Savant Instruments, Farmingdale, NY, USA), then
resuspended in 1.5mL ddH2O.
2.2. Determinationofproteinconcentration
2.2.1. Column-puriﬁedsampleconcentration
The concentration of subtilosin in the column-puriﬁed frac-
tion was determined using the Micro BCA Protein Assay Kit
according to the manufacturer’s protocol (Pierce, Rockford,
Ill, USA). In brief, the assay measures the reduction of Cu2+
to Cu1+ by colorimetric detection of Cu1+ by bicinchoninic
acid. Bovine serum albumin (BSA) was used to develop
a standard curve with concentrations ranging from 0.5 to
20μg/mL; the concentration of subtilosin was calculated
using the R value from the trendline of the standard curve
graph.
2.2.2. AssayofsubtilosinconcentrationinCFS
The concentration of subtilosin in the CFS was not mea-
surable with the Micro BCA Protein Assay due to the
high level of background proteins in the solvent (MRS
medium). As an alternative, the protein concentration was
calculated by comparing the antimicrobial activity of known
concentrations of column-puriﬁed protein to equal volumes
of CFS. Five two-fold dilutions were made from the stock
samples of both the CFS and the column-puriﬁed fraction.
Well diﬀusion assays were performed using 50μLo fe a c h
dilution against Micrococcus luteus ATCC 10420, which
is commonly used as a reference microorganism for the
determination of a bacteriocin’s biological activity [28].
2.3. Determinationofthepresenceof
weakorganicacids
As reported previously, the concentration of lactic acid in
the CFS was measured to assess its potential eﬀects on
antimicrobial activity and cell viability [2]. The quantity
of each form of the acid in the sample was measured
using a commercially available D-lactic acid/L-lactic acid kit
(Roche Boehringer, Mannheim, Germany), according to the
manufacturer’s instructions.
2.4. EpiVaginalectocervicaltissuemodel
The EpiVaginal (VEC-100) ectocervical tissue model (Mat-
Tek Corporation, Ashland, Mass, USA) was used and
maintainedasfullydescribedbyDoveretal.[29].Thetissues
were exposed to 83μL of subtilosin CFS (∼136μg/mL) for
4, 24, and 48 hours. For exposure times over 24 hours, the
tissues were aerated by placing them on two metal washers
(MatTek Corporation, Ashland, Mass, USA) and fed with
5mL of the assay medium. Double-distilled water (ddH2O)
was used as a negative control, and was applied to cells
after 6, 24, and 48 hours. A spermicidal product containing
4% Nonoxynol-9 (Ortho Options CONCEPTROL Vaginal
Contraception Gel, Advanced Care Products, Skillman, NJ,
USA) was used as a positive control based on its documented
cytotoxic properties [30, 31]. A cream (Monistat-3, Ortho
McNeil Pharmaceutical, Inc., Raritan, NJ, USA) containing
4% of the nontoxic, BV-active compound miconazole nitrate
[30, 31], was used as a negative control.Katia E. Sutyak et al. 3
Followingthedesignatedexposuretimes,theMTT(3-(4,
5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide)
assay was used to determine overall cell viability. The data
were used to approximate an eﬀective time (ET) that would
reduce cell viability to 50% (ET-50).
2.5. MTTviabilityassay
The MTT assay was carried out according to the protocol
outlined by Dover et al. [29]. Brieﬂy, the viability of
ectocervical cells after exposure to subtilosin was measured
as a direct proportion of the breakdown of the yellow
compound tetrazolium to the purple compound formazan,
since only living cells can cause this reaction to occur [32].
Tissues were exposed to subtilosin and the two controls
for several designated time points; at the conclusion of
each, the liquid in the plate wells was combined with the
liquid from the tissue inserts. This mixture was then assayed
spectrophotometrically using a 96 well-plate reader (MRX
revelation, Dynex Technologies, Va, USA) to determine the
level of tetrazolium degradation.
The viability (%) of the treated tissue inserts was
calculated according to an equation provided by the man-
ufacturer: % viability = OD570 (treated tissue)/OD570
(negative control tissue). The exposure time that reduced
tissue viability by 50% (ET-50) was calculated according to
[V = a + b∗log(t)] described by Ayehunie et al. [30], where
V = % viability, t = time in minutes, and “a”a n d“ b”a r e
constantsrepresentingtheviabilitydatafromthetimepoints
preceding and following 50% viability. On the whole, there
is a direct relationship between the length of the ET-50 and
the toxicity of the tested application (i.e., a shorter ET-50
corresponds to a more harmful compound).
2.6. Semensamplecollectionandanalysis
The CFS gathered from a B. amyloliquefaciens culture was
used to test the eﬀect of subtilosin exposure on the motility
of human spermatozoa. Initially, the CFS was diluted with
normal saline (0.9%) so that 200μL of the ﬁnal material was
equivalent to 50μL, 100μL, or 200μL of undiluted CFS.
Two semen samples were collected on the day of experi-
mentation. Each sample was collected by self-masturbation
in a polypropylene specimen container (Fisher) prior to
transport to the laboratory. Within 1 hour of collection, the
samples werepooled. Total sperm count wascalculatedusing
bright ﬁeld light microscopy (Olympus BX50; 400x) after
dilution (1:50) of the semen in normal saline. The initial
percentage of motile sperm was calculated prior to testing
with a neubauer hemacytometer [33]. The determination
of motile sperm % was made using randomly selected ﬁeld
views (400x) from a count of between 104–201 cells. Any
visibly moving spermatozoa (directional or stationary) were
counted as motile cells.
The percentage of forward progressing spermatozoa was
subjectively determined based on the assumption that 70%
of the sperm in a normal sample would behave in such a
manner. The samples used in this experimentation fell into
such a “normal” category.
2.7. Treatmentofspermatozoawithsubtilosin
A modiﬁed Sander-Cramer test was used to determine the
eﬀect of column-puriﬁed subtilosin on human spermatozoa
motility [34]. This measured the eﬀect of subtilosin after 30-
second exposure times of 5 volumes (200μL) of the solution
at each dilution (25% and 50% in normal saline, and 100%)
with one volume (40μL) of whole semen. The motilities of
cells from random high-magniﬁcation ﬁelds (400x) of the
sample were determined in duplicate as described above.
2.8. Dataanalysis
The % motility data were arcsine transformed [35]p r i o r
to further examination. StatMost32 (version 4.1) statistical
software (DataMost Corporation, Sandy, Utah, USA) was
used to calculate all statistical parameters. The % values of
motility were presented as averages and 90% conﬁdence lim-
its. Any diﬀerences between treatment groups were assessed
by the Newman-Keuls multiple range test. Diﬀerences were
deemed signiﬁcant at the 0.05 level of conﬁdence.
3. RESULTS
3.1. Determinationofproteinconcentration
The concentration of subtilosin in the column-puriﬁed
sample was estimated at 135.7μg/mL. The CFS and column-
puriﬁed sample produced identical zones of inhibition at
eachdilution(datanotshown);therefore,theconcentrations
of protein in both solutions were assumed to be equivalent.
While it is improbable that a 100% yield would be attained
from column chromatography, previous work has shown
that protein concentrations can be precisely calculated based
on the comparisons we conducted [36]. Due to the diﬃculty
in measuring the CFS protein concentration via other assays,
the chosen method was deemed the most accurate and
reproducible.
3.2. Cellviability%andET-50values
After 48 hours of exposure to subtilosin, the EpiVaginal
ectocervicaltissuesretainedahighlevelofviabilitycompared
to the positive control, Nonoxynol-9, and the negative
control, miconazole nitrate (Table 1). Due to the lack of
toxicity of the antimicrobial, the ET-50 value for subtilosin
could not be established since the total cell viability did not
drop below 50% at any of the given time points. However, a
projection of the ET-50 value is possible by an extrapolation
of the data. Data presented in Table 1 can be ﬁt to a curve
described by Ln(V) = a + bt2,w h e r ea = 4.605995356
and b =− 0.00014151 (coeﬃcient of determination, or r2,
= 0.9998), from which the ET-50 is estimated at 70 hours.
3.3. Quantitativeobservationsofmotilespermatozoa
Subtilosin reduces human sperm motility in a dose-
dependent manner (Figure 1). The motility of the treated
spermatozoa ranged from 0 to 88% of control motility
levels over the four-fold range of subtilosin concentrations.4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Ectocervical cell viability after prolonged exposure to subtilosin.
Postexposure cell viability (%)
Exposure time (hrs) Assay # Subtilosin Nonoxynol-9 (4%) Miconazole nitrate (4%) ddH2O
4 1 99.1 14.1 ND 100
2 100 16.5 ND 100
24 1 94.8 0 58.4 100
2 89.8 0 58.3 100
48 1 73.4 0 79.3 100
2 70.9 0 83.5 100
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Figure 1: Subtilosin A immobilizes human spermatozoa in a
dose-dependent manner. The percentage of motile spermatozoa in
pooled whole semen was determined 30 seconds after mixing with
subtilosin A, at diﬀerent ﬁnal concentrations, as indicated. All data
were adjusted to a normal control motility of 70% and subjected to
arcsine transformation before further analysis. Values are expressed
as average % motility. Error bars are 90% conﬁdence limits.
All of the subtilosin concentrations tested reduced motility
compared to the control samples. The diﬀerences in the
proportion of motile spermatozoa in all samples (28.3,
56.7, and 113.3μg/m Lp r o t e i ne q u i v a l e n t s )w e r ef o u n dt o
be signiﬁcant (P<. 05) according to the Newman-Keuls
multiple range test. TableCurve 2D (ver 5.0) curve-ﬁtting
software (SPSS Scientiﬁc Software, Chicago, Ill, USA) was
used to ﬁt the data to a dose-response curve described by Ln
(% Motility) = a + b[Subtilosin A]3,w h e r ea = 4.20781;
b =− 2.5814e − 06; and [subtilosin A] is expressed as
μg/mL protein equivalents. The curve had a coeﬃcient of
determination (r2) = 0.9959. The IC50 value, or the amount
of subtilosin required to reduce the motility of spermatozoa
in whole semen by 50%, was calculated to be 64.5μg/mL.
3.4. Semiquantitativeobservationsof
spermatozoa:forwardprogression
Similar to motility, forward progression of spermatozoa is
reducedinadose-dependentfashionbysubtilosin.Incontrol
samples, 70% of sperm exhibited forward progression; in the
presence of 50μL subtilosin this decreased to 50–70%, while
100μL caused a decline to only 10% forward progression.
All forward progression was eliminated after treatment with
200μL subtilosin, with most sperm tails becoming coiled.
4. DISCUSSION
TheB.amyloliquefaciens-producedbacteriocinsubtilosinhas
proven antimicrobial activity against the vaginal pathogen
G. vaginalis, but was not harmful to the normal and
healthy Lactobacillus vaginal microbiota. Data from human
vaginal cell viability assays convincingly demonstrated the
safety of subtilosin for human applications in comparison
to other accepted and available products, indicating it
could be safely incorporated into personal care applications
aimed at the treatment of bacterial vaginosis. Prior research
in our laboratory that involved similar studies with the
EpiVaginal model was also carried out in conjunction with
in vivo testing of the rabbit vaginal irritation (RVI) system,
which doubly conﬁrmed the safety of another antimicrobial
peptide, Lactocin 160 [29]. Therefore, we are conﬁdent that
using the EpiVaginal model instead of animal testing to
demonstratethesafetyofsubtilosinhasprovidedreliableand
valid results.
Subtilosin was also found to signiﬁcantly reduce
the motility of human spermatozoa in a concentration-
dependent manner for all concentrations tested. The eﬀect
of subtilosin on the forward progression of spermatozoa
was also observed to be a dose-dependent interaction. Serial
dilutions showed a steady decline in forward progression,
with all progression halted at the highest concentration
tested. It was also noted that at the highest concentration,
the tails of the sperm cells were curved or coiled, indicating
the cells were damaged beyond a simple restriction of
movement. Coiling of the cells is considered to be a
sperm abnormality, and may indicate damage to the plasma
membrane [37]. Tail coiling has been observed after in vitro
exposure of monkey spermatozoa to methyl mercury [38].
These results suggest that subtilosin can be established as
a general spermicidal agent. It is worth noting that nisin,
a bacteriocin given generally recognized as safe (GRAS)
status by the Food and Drug Administration (FDA), was also
showntohaveimpressivespermicidalactivity[25].However,
the allure of these results is diminished due to the fact that it
also has potent antimicrobial activity against healthy vaginal
microbiota (Chikindas et al., unpublished data), a strongKatia E. Sutyak et al. 5
detraction from its commercial applicability. Therefore,
subtilosin’s spermicidal activity, combined with its overall
safety to both human tissues and healthy human microbiota,
make it a highly recommendable compound for inclusion in
topicalBVtreatmentsandhumancontraceptiveproducts.To
facilitate the process of its incorporation into contraceptive
treatments, additional analysis will be done to determine the
reversibility of damage done to the spermatozoa, as well as
a time course assay to further elucidate the exact changes
eﬀected by subtilosin.
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